NEW YORK (Reuters Health) Nov 27 - Concern that estrogen depletion in women with breast cancer may contribute to cognitive compromise does not appear to be warranted, at least over the short term, according to a report in the November 1st issue of Cancer.
"Antiestrogen therapy with tamoxifen or aromatase inhibitors did not have any significant effects on cognitive function, and I think it is safe to say that patients needn't worry about cognitive side effects of these medications," Dr. Kerstin Hermelink from Ludwig Maximilian University, Munich, Germany, told Reuters Health.
Dr. Hermelink and colleagues assessed the effects of induced menopause and antiestrogen therapy on cognitive function in 101 women with nonmetastatic, invasive breast cancer.
At about 7 months after the completion of neoadjuvant therapy, the cognitive performance of the overall group, and of all subgroups based on menopausal status and antiestrogen therapy, ranged within or above the test norms on all cognitive tests, the investigators report.
In fact, they say, the effects of induced menopause on cognitive function appeared to be positive in some tests.
"In our study, cognitive compromise was already present before any cancer treatment," Dr. Hermelink explained. "Several other prospective studies have also found pretreatment cognitive dysfunction. Therefore, cognitive compromise in cancer patients must at least in part have other causes than the cancer therapy. We presume that stress might play an important role."
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου